{"id":49618,"date":"2025-12-01T16:32:22","date_gmt":"2025-12-01T08:32:22","guid":{"rendered":"https:\/\/flcube.com\/?p=49618"},"modified":"2025-12-01T16:32:23","modified_gmt":"2025-12-01T08:32:23","slug":"iregenes-nouvneu004-wins-fda-special-exemption-for-msa-cell-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49618","title":{"rendered":"iRegene&#8217;s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>iRegene Therapeutics<\/strong> announced that the <strong>U.S. FDA<\/strong> granted <strong>Special Exemption status<\/strong> to <strong>NouvNeu004 injection<\/strong>, approving an <strong>international Phase\u202fI clinical trial<\/strong> for <strong>Multiple System Atrophy (MSA)<\/strong>, making it the <strong>world\u2019s first MSA cell therapy product<\/strong> to enter clinical development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>NouvNeu004 injection<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>iRegene Therapeutics (China\u2011based)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Special Exemption granted; International Phase\u202fI approved<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Multiple System Atrophy (MSA)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>World\u2019s first MSA cell therapy<\/strong> to enter clinical stage<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Initiate international Phase\u202fI trial Q1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Chemically\u2011induced, <strong>function\u2011enhanced neural progenitor cells<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Strategy:<\/strong> <strong>\u201cNeurotrophy + Neuro\u2011reconstruction\u201d<\/strong> \u2014 dual approach to support and rebuild neural networks<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First cell therapy targeting MSA, a rapidly progressive neurodegenerative disorder<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Intrathecal injection<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>U.S. MSA Prevalence<\/strong><\/td><td>~15,000\u201150,000 patients (rare disease)<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Symptomatic management only; <strong>no disease\u2011modifying therapy<\/strong> approved<\/td><\/tr><tr><td><strong>Cell Therapy Market<\/strong><\/td><td>$18\u202fbillion globally (2024); neuro\u2011degenerative segment emerging<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td><strong>First\u2011in\u2011class<\/strong>; no other MSA cell therapies in late\u2011stage development<\/td><\/tr><tr><td><strong>Pricing Potential<\/strong><\/td><td>$200,000\u2011400,000 per treatment (rare disease cell therapy benchmark)<\/td><\/tr><tr><td><strong>Peak Sales Forecast<\/strong><\/td><td><strong>$300\u2011500\u202fmillion<\/strong> (global peak) if Phase\u202fI data support advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Special Exemption Impact:<\/strong> Allows <strong>expedited trial design<\/strong> and potential <strong>rolling review<\/strong>, bypassing certain regulatory steps to accelerate development<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Positions iRegene as a <strong>pioneer in neuro\u2011degenerative cell therapy<\/strong> with platform potential for other CNS disorders<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NouvNeu004\u2019s clinical development, regulatory pathway, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, safety profiles, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[1218,24],"class_list":["post-49618","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-iregene-therapeutics","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>iRegene&#039;s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving an international Phase\u202fI clinical trial for Multiple System Atrophy (MSA), making it the world\u2019s first MSA cell therapy product to enter clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49618\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iRegene&#039;s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy\" \/>\n<meta property=\"og:description\" content=\"iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving an international Phase\u202fI clinical trial for Multiple System Atrophy (MSA), making it the world\u2019s first MSA cell therapy product to enter clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49618\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-01T08:32:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T08:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"iRegene&#8217;s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy\",\"datePublished\":\"2025-12-01T08:32:22+00:00\",\"dateModified\":\"2025-12-01T08:32:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618\"},\"wordCount\":285,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0102.webp\",\"keywords\":[\"iRegene Therapeutics\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49618#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49618\",\"name\":\"iRegene's NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0102.webp\",\"datePublished\":\"2025-12-01T08:32:22+00:00\",\"dateModified\":\"2025-12-01T08:32:23+00:00\",\"description\":\"iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving an international Phase\u202fI clinical trial for Multiple System Atrophy (MSA), making it the world\u2019s first MSA cell therapy product to enter clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49618\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0102.webp\",\"width\":1080,\"height\":608,\"caption\":\"iRegene's NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49618#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iRegene&#8217;s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"iRegene's NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving an international Phase\u202fI clinical trial for Multiple System Atrophy (MSA), making it the world\u2019s first MSA cell therapy product to enter clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49618","og_locale":"en_US","og_type":"article","og_title":"iRegene's NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy","og_description":"iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving an international Phase\u202fI clinical trial for Multiple System Atrophy (MSA), making it the world\u2019s first MSA cell therapy product to enter clinical development.","og_url":"https:\/\/flcube.com\/?p=49618","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-01T08:32:22+00:00","article_modified_time":"2025-12-01T08:32:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49618#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49618"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"iRegene&#8217;s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy","datePublished":"2025-12-01T08:32:22+00:00","dateModified":"2025-12-01T08:32:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49618"},"wordCount":285,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49618#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102.webp","keywords":["iRegene Therapeutics","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49618#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49618","url":"https:\/\/flcube.com\/?p=49618","name":"iRegene's NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49618#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49618#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102.webp","datePublished":"2025-12-01T08:32:22+00:00","dateModified":"2025-12-01T08:32:23+00:00","description":"iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving an international Phase\u202fI clinical trial for Multiple System Atrophy (MSA), making it the world\u2019s first MSA cell therapy product to enter clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49618#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49618"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49618#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102.webp","width":1080,"height":608,"caption":"iRegene's NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49618#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"iRegene&#8217;s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49618"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49618\/revisions"}],"predecessor-version":[{"id":49621,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49618\/revisions\/49621"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49620"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}